Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $10.40, but opened at $9.95. Mesoblast shares last traded at $9.96, with a volume of 31,208 shares trading hands.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. Cantor Fitzgerald raised shares of Mesoblast to a "strong-buy" rating in a research report on Monday, March 31st. Finally, Piper Sandler restated an "overweight" rating and set a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Mesoblast has an average rating of "Moderate Buy" and a consensus target price of $18.00.
Check Out Our Latest Analysis on Mesoblast
Mesoblast Trading Up 0.3 %
The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The company has a 50 day moving average of $14.28 and a 200-day moving average of $13.55.
Hedge Funds Weigh In On Mesoblast
A number of large investors have recently bought and sold shares of MESO. R Squared Ltd acquired a new position in Mesoblast during the 4th quarter valued at approximately $30,000. Barclays PLC acquired a new stake in shares of Mesoblast in the 4th quarter worth about $38,000. Lindbrook Capital LLC lifted its position in Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after purchasing an additional 901 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Mesoblast in the 4th quarter worth about $50,000. Finally, BNP Paribas Financial Markets grew its holdings in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after buying an additional 2,597 shares in the last quarter. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Recommended Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
